Nakagawa · American journal of physiology. Renal physiology 2006 · controlled animal interventional study and ex vivo tissue assay · n=?

A causal role for uric acid in fructose-induced metabolic syndrome.

Cited 1105 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical animal interventional experiment and ex vivo tissue assays without human subjects.

PubMed 16234313 · doi:10.1152/ajprenal.00140.2005 · record verified 2026-08-29

What was done

Researchers evaluated the causal role of uric acid in fructose-induced metabolic syndrome across four experiments in rats. First, pair-feeding compared diets containing fructose versus dextrose. Second, rats on a high-fructose diet were treated with uric acid-lowering agents (the xanthine oxidase inhibitor allopurinol or the uricosuric agent benzbromarone) to test prevention and reversal of metabolic abnormalities. Third, dietary intake on a control diet was assessed during drug administration. Fourth, the effect of uric acid on endothelial function was tested ex vivo using vasodilatory responses to acetylcholine in rat aortic rings.

What was found

Pair-fed fructose, but not dextrose, induced hyperinsulinemia, hypertriglyceridemia, and hyperuricemia. In fructose-fed rats, prophylactic allopurinol significantly prevented hyperinsulinemia (160.8 vs. 272.3 pmol/l, P < 0.05), systolic hypertension (133 vs. 142 mmHg, P < 0.05), hypertriglyceridemia (65.4 vs. 233.7 mg/dl, P < 0.01), and weight gain (425 vs. 455 g, P < 0.05) at 8 weeks. Neither allopurinol nor benzbromarone altered dietary intake in control rats. In aortic rings, uric acid dose-dependently inhibited acetylcholine-induced vasodilation.

Why it matters

This study provides experimental evidence that hyperuricemia directly drives fructose-induced metabolic syndrome features, potentially through endothelial dysfunction and impaired nitric oxide bioavailability.

Limits

The study was conducted entirely in rodent and ex vivo tissue models, leaving human relevance unconfirmed. The abstract does not report group sample sizes (n) or exact values for benzbromarone effects and the ex vivo vascular assays.

Cited by